When Global Tensions Hit Supply Chains: Understanding India’s Pharma Export Dip in March
April 20, 2026
India’s biotechnology sector is no longer an emerging story—it is a rapidly accelerating force. Valued at nearly $195 billion in 2025 and contributing close to 5% of GDP, the country’s bioeconomy has grown almost twenty-fold over the past decade. Yet, as policymakers set their sights on a $1 trillion bioeconomy by 2047, the challenge is no longer just innovation—it is scale, competitiveness, and global leadership.
At the heart of this transformation lies the Biotechnology Industry Research Assistance Council (BIRAC), an institution that has played a foundational role in nurturing India’s biotech startup ecosystem. But as highlighted in recent policy discussions, the next phase of growth demands a reinvention of BIRAC itself—from a grant-giving body to a catalyst for bio-industrial scale.
From Startup Support to Industrial Scale
Over the past decade, BIRAC has successfully funded thousands of startups, contributing to a vibrant ecosystem of more than 11,800 biotech ventures. This model—focused on early-stage innovation through grants and seed funding—was essential in building India’s scientific base.
However, the limitations of this approach are becoming evident. While startups are flourishing, very few have transitioned into globally competitive bio-manufacturing companies. The gap lies in scaling technologies from lab to market, a phase that requires patient capital, infrastructure, and long-term industrial strategy rather than short-term grants.
To bridge this gap, India must shift its focus from “innovation creation” to “innovation commercialization.” That means supporting companies not just to invent, but to manufacture, export, and compete globally.
The Missing Middle: Scale-Up Infrastructure
One of the biggest bottlenecks in India’s bioeconomy is the lack of scale-up infrastructure. Biotech innovation is capital-intensive and requires specialized facilities—bioreactors, pilot plants, and regulatory support systems. Without these, promising technologies often fail to reach commercial viability.
Recent initiatives, such as high-performance biomanufacturing platforms, signal a step in the right direction. These aim to provide shared infrastructure for startups and SMEs, improving efficiency and reducing costs. But these efforts need to be expanded and integrated into a broader national strategy.
BIRAC must evolve into a platform that not only funds innovation but also builds ecosystems—clusters where academia, industry, and investors collaborate to create scalable bio-industrial solutions.
Building Global Supply Chains
If India aims to become a bioeconomy powerhouse, it must also rethink its position in global supply chains. Today, much of the value addition in biotechnology happens outside India, even when the underlying innovation originates domestically.
The future lies in creating sustainable, resilient, and export-oriented supply chains. This includes everything from bio-based raw materials to finished pharmaceutical and industrial products. A strong domestic manufacturing base will not only boost exports but also reduce dependence on imports—an issue highlighted during global disruptions like the COVID-19 pandemic.
BIRAC’s role here could expand to facilitating industry partnerships, enabling technology transfer, and supporting companies in meeting global regulatory standards.
Financing the Bioeconomy of Tomorrow
Another critical challenge is financing. Traditional grant-based funding is insufficient for scaling biotech ventures, which often require long gestation periods and high-risk investments.
Experts argue for new financial instruments—venture debt, blended finance, and even dedicated biotech stock exchange platforms—to attract long-term capital. Without these, India risks losing its most promising innovations to global markets where funding ecosystems are more mature.
BIRAC could play a pivotal role by acting as a bridge between public funding and private investment, de-risking projects and attracting institutional capital.
The Road to $1 Trillion
India’s bioeconomy is projected to reach $300 billion by 2030, a significant milestone on the path to the trillion-dollar goal. However, achieving this vision will require more than incremental progress. It demands a structural shift in how innovation is supported, scaled, and commercialized.
The message is clear: India must move beyond being a startup hub to becoming a global biomanufacturing leader. This transformation will require bold policy reforms, deeper industry collaboration, and a reimagined role for institutions like BIRAC.
In the race toward a $1 trillion bioeconomy, the question is no longer whether India can innovate—but whether it can scale.
